Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
Eli Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Comparable A1C Reduction To Daily Insulin Degludec In Phase 3 QWINT-2 Trial; Results Published In NEJM And Presented At EASD 2024; Efsitora Reduced A1C By 1.34% Compared To 1.26% For Insulin Degludec
In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand1,2, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively3 at 52 weeks.In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7%
在 qWint-2 中，efsitora 帮助对胰岛素治疗天真的成年人目前正在使用和未使用 GLP-1 受体激动剂的 A1C 降至 7% 以下
Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
详细结果发表在《新英格兰医学杂志》上，并同时在2024年欧洲糖尿病研究协会（EASD）年会上发表
INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin naïve). The data were published in The New England Journal of Medicine (NEJM) and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.
印第安纳波利斯，2024年9月10日 /PRNewswire/ — 礼来公司（纽约证券交易所代码：LLY）今天公布了QWint-2三期试验的详细结果，该试验评估了首次使用胰岛素的2型糖尿病成年人每周一次的efsitora alfa（efsitora），与首次使用胰岛素（胰岛素天真）的2型糖尿病成人每天服用一次胰岛素的比较。这些数据发表在《新英格兰医学杂志》（NEJM）上，并于今天在欧洲糖尿病研究协会（EASD）2024年年会上同时发布。
In the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand1,2, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively3 at 52 weeks.
在试验中，efsitora达到了非劣质A1C还原的主要终点。据估计，功效1,2，efsitora将A1C降低了1.34％，而胰岛素degludec的A1C为1.26％，因此在52周时，A1C分别为6.87％和6.95％3。
Additionally, participants taking efsitora achieved 45 minutes more time in range4 per day, a key secondary endpoint, without additional time in hypoglycemia (glucose <54 mg/dL) in comparison to insulin degludec for the efficacy estimand.
此外，在疗效评估中，服用efsitora的参与者在每天4范围内的时间延长了45分钟，这是一个关键的次要终点，与degludec胰岛素相比，没有额外的低血糖时间（葡萄糖
